Assessment of p27 (cyclin-dependent kinase inhibitor 1B) and aryl hydrocarbon receptor-interacting protein (AIP) genes in multiple endocrine neoplasia (MEN1) syndrome patients without any detectable MEN1 gene mutations - PubMed
Assessment of p27 (cyclin-dependent kinase inhibitor 1B) and aryl hydrocarbon receptor-interacting protein (AIP) genes in multiple endocrine neoplasia (MEN1) syndrome patients without any detectable MEN1 gene mutations
Susana Igreja et al. Clin Endocrinol (Oxf). 2009 Feb.
Abstract
Objective: Germline mutations in the MEN1 gene predispose to the multiple endocrine neoplasia (MEN1) syndrome; however, approximately 10-20% of patients with MEN1 do not have a detectable MEN1 mutation. A rat strain with multiple endocrine tumours, a phenotypic overlap of both MEN1 and MEN2, has been reported to have a homozygous germline p27 (CDKN1B) mutation. Recently, two MEN1 mutation-negative MEN1 syndrome patients have been identified to harbour a germline CDKN1B mutation. The recently identified gene AIP can also cause familial isolated pituitary adenoma, but no other specific tumour is associated with this syndrome. The objective of this study was to evaluate the possible contribution of CDKN1B and AIP germline mutations in a cohort of MEN1 mutation-negative MEN1 syndrome patients.
Patients: Eighteen sporadic and three familial cases of MEN1 mutation-negative MEN1 syndrome were studied (18 pituitary adenomas, 12 hyperparathyroidism, 10 neuroendocrine tumours including 2 ACTH-secreting lesions and one adrenal nodular hyperplasia). Clinical data and genomic DNA were analysed for mutations in the CDKN1B and AIP genes.
Results: There were no mutations in the coding region or exon/intron junction of the CDKN1B and AIP genes in any patient. Although we have a limited number of patients in our cohort, our data is consistent with others in the literature suggesting that CDKN1B and AIP mutations are extremely rare in MEN1 syndrome.
Conclusion: Our results suggest that mutations in the CDKN1B and AIP genes are relatively uncommon in MEN1 mutation-negative MEN1 syndrome patients.
Similar articles
-
Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia.
Georgitsi M, Raitila A, Karhu A, van der Luijt RB, Aalfs CM, Sane T, Vierimaa O, Mäkinen MJ, Tuppurainen K, Paschke R, Gimm O, Koch CA, Gündogdu S, Lucassen A, Tischkowitz M, Izatt L, Aylwin S, Bano G, Hodgson S, De Menis E, Launonen V, Vahteristo P, Aaltonen LA. Georgitsi M, et al. J Clin Endocrinol Metab. 2007 Aug;92(8):3321-5. doi: 10.1210/jc.2006-2843. Epub 2007 May 22. J Clin Endocrinol Metab. 2007. PMID: 17519308
-
Belar O, De La Hoz C, Pérez-Nanclares G, Castaño L, Gaztambide S; Spanish MEN1 Group. Belar O, et al. Clin Endocrinol (Oxf). 2012 May;76(5):719-24. doi: 10.1111/j.1365-2265.2011.04269.x. Clin Endocrinol (Oxf). 2012. PMID: 22026581
-
Vierimaa O, Villablanca A, Alimov A, Georgitsi M, Raitila A, Vahteristo P, Larsson C, Ruokonen A, Eloranta E, Ebeling TM, Ignatius J, Aaltonen LA, Leisti J, Salmela PI. Vierimaa O, et al. J Endocrinol Invest. 2009 Jun;32(6):512-8. doi: 10.1007/BF03346498. Epub 2009 Mar 26. J Endocrinol Invest. 2009. PMID: 19474519
-
Chevalier B, Coppin L, Romanet P, Cuny T, Maïza JC, Abeillon J, Forestier J, Walter T, Gilly O, Le Bras M, Smati S, Nunes ML, Geslot A, Grunenwald S, Mouly C, Arnault G, Wagner K, Koumakis E, Cortet-Rudelli C, Merlen É, Jannin A, Espiard S, Morange I, Baudin É, Cavaille M, Tauveron I, Teissier MP, Borson-Chazot F, Mirebeau-Prunier D, Savagner F, Pasmant É, Giraud S, Vantyghem MC, Goudet P, Barlier A, Cardot-Bauters C, Odou MF. Chevalier B, et al. J Clin Endocrinol Metab. 2024 Jun 17;109(7):e1482-e1493. doi: 10.1210/clinem/dgae055. J Clin Endocrinol Metab. 2024. PMID: 38288531 Review.
-
Susceptibility to pituitary neoplasia related to MEN-1, CDKN1B and AIP mutations: an update.
Karhu A, Aaltonen LA. Karhu A, et al. Hum Mol Genet. 2007 Apr 15;16 Spec No 1:R73-9. doi: 10.1093/hmg/ddm036. Hum Mol Genet. 2007. PMID: 17613551 Review.
Cited by
-
Genetics of Acromegaly and Gigantism.
Bogusławska A, Korbonits M. Bogusławska A, et al. J Clin Med. 2021 Mar 29;10(7):1377. doi: 10.3390/jcm10071377. J Clin Med. 2021. PMID: 33805450 Free PMC article. Review.
-
Agarwal SK, Mateo CM, Marx SJ. Agarwal SK, et al. J Clin Endocrinol Metab. 2009 May;94(5):1826-34. doi: 10.1210/jc.2008-2083. Epub 2009 Jan 13. J Clin Endocrinol Metab. 2009. PMID: 19141585 Free PMC article.
-
Lips CJ, Dreijerink KM, Höppener JW. Lips CJ, et al. Clinics (Sao Paulo). 2012;67 Suppl 1(Suppl 1):49-56. doi: 10.6061/clinics/2012(sup01)10. Clinics (Sao Paulo). 2012. PMID: 22584706 Free PMC article. Review.
-
MEN1 redefined, a clinical comparison of mutation-positive and mutation-negative patients.
de Laat JM, van der Luijt RB, Pieterman CR, Oostveen MP, Hermus AR, Dekkers OM, de Herder WW, van der Horst-Schrivers AN, Drent ML, Bisschop PH, Havekes B, Vriens MR, Valk GD. de Laat JM, et al. BMC Med. 2016 Nov 15;14(1):182. doi: 10.1186/s12916-016-0708-1. BMC Med. 2016. PMID: 27842554 Free PMC article.
-
Chasseloup F, Pankratz N, Lane J, Faucz FR, Keil MF, Chittiboina P, Kay DM, Hussein Tayeb T, Stratakis CA, Mills JL, Hernández-Ramírez LC. Chasseloup F, et al. J Clin Endocrinol Metab. 2020 Jun 1;105(6):1983-2005. doi: 10.1210/clinem/dgaa160. J Clin Endocrinol Metab. 2020. PMID: 32232325 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous